Physician profile
Ryan Brown
NPI 1760826275
$3,850.86
in general payments reported to CMS, 2019-2025
33 companies · $907 in 2025
The $907 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $697 · 2023: $779 · 2024: $996 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,616.09 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $421.92 | 2021-2025 | |
| Amgen INC. | $371.49 | 2021-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $349.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $249.13 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $249.11 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $221.32 | 2021-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Glaxosmithkline, LLC. | $216.68 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $210.89 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $148.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.02 | 2022-2023 | Jardiance, Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $91.89 | 2021-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $84.85 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $65.57 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $65.31 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $54.85 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.06 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $38.15 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $36.38 | 2025 | Vowst |
| Amarin Pharma, INC. | $33.69 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $32.03 | 2021 | |
| Mylan Specialty L.P. | $26.06 | 2021 | |
| Daiichi Sankyo INC. | $23.37 | 2021 | |
| Esperion Therapeutics, INC. | $23.03 | 2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.80 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.61 | 2022 | |
| Biogen, INC. | $19.15 | 2024 | Spinraza |
| Lundbeck LLC | $18.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.50 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.21 | 2021 | |
| Abbott Laboratories | $12.79 | 2021 | |
| Eisai INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.